使用α-Synuclein ((Y136C) -金纳米粒子结合物进行针对细胞核的抗癌药物递送
Jeongha Park1, Seung R Paik1,2
1School of Chemical and Biological Engineering, Institute of Engineering Research, College of Engineering, Seoul National University, Seoul 08826, Republic of Korea.
ACS materials Au
|November 17, 2025
概括
这项研究引入了一种新的纳米粒子系统,使用与α-synuclein结合的金纳米粒子直接向细胞核输送多克索鲁比,以加强癌症治疗.
科学领域:
- 生物技术是生物技术.
- 纳米医学是一种纳米医学.
- 癌症研究 癌症研究
背景情况:
- 细胞核对于真核细胞的生存至关重要,也是癌症治疗的关键目标.
- 传统的核导向抗癌药物,如多克索鲁比辛 (Dox),在细胞吸收和核递送方面表现出局限性.
- 基于纳米粒子的系统为克服这些药物输送挑战提供了潜在的解决方案.
研究的目的:
- 开发一种细胞内药物输送系统,用于向细胞核的癌症治疗.
- 为了利用α-synuclein-gold纳米粒子结合物 (αS-AuNPs) 增强药物递送和核积累.
- 通过近红外 (NIR) 辐射和光热效应实现可控的药物释放.
主要方法:
- α-synuclein (αS) 与黄金纳米粒子 (AuNPs) 的结合形成了αS-AuNPs.
- 通过可热性交叉链接器将多克索鲁比辛 (Dox) 与αS-AuNPs结合起来.
- 利用NIR辐射触发光热效应并诱导局部高热度以释放药物.
- 评估Dox-αS-AuNP系统在向细胞核的癌症治疗中的有效性.
主要成果:
- αS-AuNPs证明了有效的细胞吸收和核积累.
- 尼尔射线照射成功触发了耐热链接器的裂变,释放了Dox.
- 由AuNPs诱导的局部高温症促进了核内受控的Dox释放.
- 通过针对核的Dox-αS-AuNP系统观察到增强的抗癌疗效.
结论:
- Dox-αS-AuNP是一种有前途的针对癌症治疗的核向药物递送系统.
- 该系统能够控制和有效地将多克索鲁比辛输送到细胞核.
- 这种方法有可能通过提高药物疗效来改善癌症治疗结果.
相关概念视频
Targeted Cancer Therapies
7.1K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.1K
Modified-Release Drug Delivery Systems: Site-Targeted
167
Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
167


